Clinical trials: Pancratic Ductal Adenocarcinoma
Pancreatic Cancer, Pancratic Ductal Adenocarcinoma
A Study of GC203 TIL in PDCA (RJ)
This study is to investigate the safety and efficacy of gene-edited tumor infiltrating lymphocyte (GC203 TIL) therapy in patients with pancreatic ductal adenocarcinoma.
- Conditions
- Pancreatic Cancer, Pancratic Ductal Adenocarcinoma, Treatment Side Effects, Tumor Infiltrating Lymphocytes
- Trial name
- NCT06828328
- Testing
- GC203 TIL
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Juncell Therapeutics
Pancreas Ductal Adenocarcinoma
Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer
Based on the superior efficacy and safety profile of liposomal irinotecan over irinotecan in pancreatic cancer, as well as preliminary results from earlier studies evaluating nab-paclitaxel and gemcitabine (AG) combined with…
- Trial name
- NCT07806110
- Testing
- SHR-1701, liposomal irinotecan+nab-paclitaxel+gemcitabine
- Where
- China
- Volunteers
- 62 people
- Sponsor
- The First Hospital of Jilin University
PDAC of the Body and the Tail of the Pancreas, CR- POPF
Oncologic Impact of Pancreatic Fistula
Clinically-relevant post-operative fistula is a major complication after DP, but it did not affect post-operative therapeutic path nor oncologic long-term outcomes.
- Trial name
- POPF-DSS (NCT04348084)
- Where
- France
- Volunteers
- 382 people
- Sponsor
- University Hospital, Montpellier